Ustekinumab 90 mg
Ustekinumab 90 mg is a pharmaceutical drug with 13 clinical trials. Currently 1 active trials ongoing. Historical success rate of 63.6%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
2
Mid Stage
9
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
63.6%
7 of 11 finished
36.4%
4 ended early
1
trials recruiting
13
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar
A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
Clinical Trials (13)
ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar
A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis
A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid
A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease
All 13 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 13